Positron Emission Tomography in Prostate Cancer

Not Applicable
Completed
Conditions
Interventions
Registration Number
NCT00121212
Lead Sponsor
Washington University School of Medicine
Brief Summary

RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
...

Detailed Description

The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
179
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Surgery - Positive PET scancarbon-11 acetate PET scanIf patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
Radiation therapy Negative or Positive PET scancarbon-11 acetate PET scanIf patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
Surgery - Negative PET scancarbon-11 acetate PET scanIf patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
Primary Outcome Measures
NameTimeMethod
Determine the role of AC-PET in changing initial patient managementCompletion of patient treatment
Secondary Outcome Measures
NameTimeMethod
Determine the value of AC-PET in predicting recurrenceMinimum of 2 years and maximum of 5 years
Assess the performance of AC-PET for detection of lymph node metastasis by comparison with biopsy.Minimum of 2 years and maximum of 5 years

Trial Locations

Locations (1)

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

🇺🇸

Saint Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath